Metabolic Selection of Transfected Cells Using 3-Ketosteroid Reductase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The biotechnology industry faces challenges in generating stable mammalian cell lines for gene expression in chemically defined, serum-free media, particularly due to cholesterol auxotrophy in cell lines like NS-0, which requires cumbersome and unstable cholesterol supplementation, leading to inconsistencies and contamination risks.
Innovation Solution
Development of expression vectors encoding enzymes in the sterol biosynthetic pathway, such as 3-ketosteroid reductase (3-KSR), to enable mammalian cells to survive and produce heterologous proteins in cholesterol-free media, using vectors like p3-KSR that include a polynucleotide encoding 3-KSR and a heterologous protein, allowing for metabolic selection and stable gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If exogenous cholesterol is added to aqueous media to support cholesterol-auxotrophic cell lines, then cell growth is enabled, but the process becomes intricate and time-consuming requiring coupling to sugar moieties
Solution Approach 1:
The patent extracts the problematic cholesterol supplementation step from the media preparation process by using cells that can synthesize their own cholesterol. The 3-KSR enzyme enables endogenous cholesterol production, eliminating the need for exogenous cholesterol addition and its associated complex coupling procedures.
Solution Approach 2:
The transfected cells become self-sufficient by expressing the 3-KSR enzyme, which enables them to synthesize cholesterol internally from available precursors. This self-service capability eliminates dependence on complex external cholesterol supplementation and allows direct addition of simple precursors like mevalonolactone.
2Productivity
If exogenous cholesterol is added to aqueous media, then cell growth is supported, but the coupling process is inherently unstable resulting in short shelf-life
Solution Approach 1:
The patent removes the unstable exogenous cholesterol component from the media system and replaces it with stable cell lines that produce cholesterol endogenously. The media itself becomes stable and can be stored indefinitely, while cells are supplied with simple, stable precursors as needed.
Solution Approach 2:
The patent changes the chemical form of cholesterol supplementation from complex coupled cholesterol esters to simple, stable precursors like mevalonolactone. These precursors are chemically stable, have long shelf-lives, and can be easily filtered and sterilized without degradation.
3Object-affected harmful factors
If chemically defined serum-free media are used instead of FBS-supplemented media, then contamination risks are reduced, but cholesterol precipitation occurs frequently
Solution Approach 1:
The cell line expresses 3-KSR to enable endogenous cholesterol synthesis from simple precursors added to the chemically defined media. This self-service capability allows the use of stable, contamination-free chemically defined media without encountering precipitation issues, as the cells produce their own cholesterol as needed.
Solution Approach 2:
The patent changes the cholesterol source from exogenous added cholesterol (which precipitates in chemically defined media) to endogenous synthesis enabled by 3-KSR expression. The cells convert simple, soluble precursors into cholesterol internally, maintaining media stability and composition consistency.
4Quantity of substance
If exogenous cholesterol is added directly to medium without filtration, then filtration losses are avoided, but contamination with adventitious agents and endotoxins increases
Solution Approach 1:
The cell line's endogenous cholesterol synthesis capability eliminates the need for any exogenous cholesterol addition, whether filtered or unfiltered. Cells produce their own cholesterol from simple, easily purified precursors, completely avoiding contamination risks associated with cholesterol handling.
Solution Approach 2:
The patent removes cholesterol from the list of substances requiring external addition and filtration. By expressing 3-KSR, cells synthesize cholesterol internally from precursors that are trivial to purify, eliminating the entire cholesterol supplementation chain and its associated contamination risks.
5Object-affected harmful factors
If cholesterol is filtered through small pore sterilizing membranes, then contamination is reduced, but cholesterol affinity to polymer membranes significantly reduces the amount in final medium
Solution Approach 1:
The 3-KSR expressing cell line produces its own cholesterol endogenously from simple precursors, eliminating any need for cholesterol filtration. This self-service approach avoids the polymer affinity problem entirely, as no cholesterol passes through membranes.
Solution Approach 2:
The patent extracts cholesterol from the filtration process by enabling endogenous synthesis. Cells produce cholesterol internally from precursors like mevalonolactone that are water-soluble and do not require special filtration handling, completely avoiding polymer affinity losses.
6Productivity
If exogenous cholesterol is added to support cholesterol-auxotrophic cell lines, then cell growth is enabled, but batch to batch inconsistencies increase
Solution Approach 1:
The patent creates self-sufficient cell lines that express 3-KSR and synthesize cholesterol endogenously from stable precursors. This eliminates batch-to-batch variability in cholesterol supplementation, as each batch of cells produces its own cholesterol consistently from identical precursor formulations.
Solution Approach 2:
The patent changes the cholesterol supplementation approach from variable exogenous addition to controlled endogenous synthesis. By providing a simple, stable precursor like mevalonolactone and enabling 3-KSR expression, the system achieves consistent cholesterol production across all cell batches, eliminating media preparation variability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables stable gene expression in chemically defined, serum-free media without exogenous cholesterol, reducing contamination risks and improving batch consistency, while allowing for the production of heterologous proteins like monoclonal antibodies.
Implementation Method 1
The 3-KSR protein catalyzes the conversion of zyrnosterone into zymosterol, a precursor of cholesterol
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
The present invention relates to novel selection marker vectors, and methods for using these vectors to generate stable gene expression systems in eukaryotic cells. More specifically, the present invention provides compositions and methods utilizing any enzyme useful in the eukaryotic sterol/cholesterol biosynthetic pathway, such as a 3-ketosteroid reductase, as a metabolic selection marker to select transfected cells. In one embodiment, the method comprises transfecting cells that are auxotrophic for cholesterol with a vector encoding 3-ketosteroid reductase and at least one heterologous protein, and selecting cells that have the ability to survive in medium lacking cholesterol and/or producing the heterologous protein in these cells in chemically defined and/or serum-free media.